Workflow
逆势进场!资金涌入创新药板块
天天基金网·2025-08-13 05:05

Core Viewpoint - The innovative drug sector has experienced a recent adjustment after a strong rally, but long-term trends remain positive, with significant capital inflows into ETFs indicating renewed investor interest [1][3][7]. Fund Flows and ETF Activity - Since the beginning of the adjustment on July 30, the net subscription amount for innovative drug-themed ETFs has exceeded 100 billion yuan, with notable contributions from various funds [3][7]. - Specific ETFs such as the GF CSI Hong Kong Innovative Drug ETF and the Huatai-PineBridge Hong Kong Innovative Drug ETF have seen net subscriptions of 28.94 billion yuan and 24.78 billion yuan, respectively [3]. - As of August 11, the total shares of the Huatai-PineBridge Hong Kong Innovative Drug ETF reached 72.47 billion, marking a new high since its launch [3]. Market Sentiment and Future Outlook - Fund managers express that while the innovative drug industry has a long-term positive trend, there will be differentiation within the sector, emphasizing the investment value of companies with strong fundamentals [1][6]. - The market is witnessing a shift of funds towards medical device sectors, indicating a strategic diversification rather than a mass exit from the innovative drug sector [7]. - The domestic policy environment is improving, enhancing the efficiency of innovative drug approvals and commercial returns, which is expected to open new market opportunities [7][8]. Performance of Active Funds - Long-term funds have been actively increasing their positions in innovative drug ETFs, with some funds like the Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund achieving over 130% returns this year [4][6]. - The valuation logic for innovative drug companies is evolving, relying more on future product sales and cash flow discount models, which suggests potential for further valuation increases as global R&D progresses [8].